Information Provided By: 
Fly News Breaks for May 8, 2017
TTPH
May 8, 2017 | 08:02 EDT
SunTrust analyst Edward Nash says that the weakness in Tetraphase's stock Friday may have been caused by a higher than expected loss per share which he blamed on on two ongoing Phase III studies. However, he thinks that data on the company's eravacyclien drug as a treatment for cIAI will be "positive." Moreover, he says that the company's balance sheet is "healthy," while its fundamentals are "strong." Nash reiterates a $14 price target and a Buy rating on the shares.
News For TTPH From the Last 2 Days
There are no results for your query TTPH
